A practical reference on metabolic research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-29 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
== Signs and symptoms == For unknown reasons, children born with FOP often have malformed big toes, sometimes missing a joint or, in other cases, simply presenting with a notable lump at the minor joint. The first "flare-up" that leads to the formation of FOP bone usually occurs before the age of 10. The bone growth generally progresses from the top of the body downward, just as bones grow in fetuses. A child with FOP will typically develop additional bones starting at the neck, then at the shoulders, arms, chest area, and finally at the feet. Specifically, ossification is typically first seen in the dorsal, axial, cranial, and proximal regions of the body. Later, the disease progresses in the ventral, appendicular, caudal, and distal regions. However, it does not necessarily occur in this order due to injury-caused flare-ups. Often, the tumor-like lumps that characterize a flare-up of the disease appear suddenly. Bone growth occurring during flare-ups may result in the loss of mobility to affected joints, including, if the jaw/mandible is involved, the inability to fully open the mouth, limiting speech and eating. Bone growth can also result in the immobilization of the hip or knee, affecting the individual's ability to walk. Extra bone formation around the rib cage restricts the expansion of lungs and diaphragm causing respiratory complications. Since the disorder is incredibly rare, only occurring in 1 out of 2 million people, the condition may be misdiagnosed as cancer or fibrosis.
=== Particles and bacteria === Particles in UPW can cause defects in semiconductors, especially in photolithographic processes that define nanometer-sized features. Particulates can interfere with etching processes and bridge nanometer-scale features in final circuits causing electrical failures. Particles can be controlled by filtration for larger particles and ultrafiltration for nanometer scale particles. Particle sources can include bacterial fragments or particles from the walls of the fluid handling system. Bacteria have been referred to as one of the most obstinate on this list to control as certain bacteria can still grow, even in low-nutrient environments. Bacteria can be controlled by sanitization or ultrafiltration (found in some pharmaceutical, but mostly semiconductor industries). Chemical sanitization can be performed using ozone or hydrogen peroxide.
Olivia Thirlby as Cassandra Anderson:A rookie Judge and genetic mutant with powerful psychic abilities. Anderson can sense the thoughts and emotions of others. Thirlby contrasted her character with Dredd's "black and white" perspective, describing Anderson as existing "in a grey area where everything is enhanced or clouded by the fact [that] she knows what is going on in the very interior of a person". She undertook weapons and combat training, learning to perform a roundhouse kick to make her believably physically commanding. The character was partially inspired by singer Debbie Harry. Lena Headey as Madeline "Ma-Ma" Madrigal: A former prostitute turned drug lord and criminal kingpin who is the sole supplier of "Slo-Mo", a new and addictive drug. Headey's performance was inspired by punk-rock singer Patti Smith. Reich described the character as someone who does "not care at all about what anybody thinks or feels and she will do, and behave, as she wants". Headey said: "I think of [Ma-Ma] like an old great white shark who is just waiting for someone bigger and stronger to show up and kill her ... she's ready for it. In fact, she can't wait for it to happen ... She's an addict, so she's dead in that way, but that last knock just hasn't come." Before Headey's casting, the character was envisioned as a heavily made-up, scarred and obese older woman. Wood Harris as Kay: Ma-Ma's clansman. Harris described the character as a villain, but one that sees himself as no worse than the Judges. Harris said: " ...
Sources: en.wikipedia.org
=== Venetoclax === BCL-2 is a cellular protein that can act to inhibit cell death due to apoptosis. The BCL-2 gene appears to be one of the most up-regulated (i.e. overactive) genes in BPDCN. Venetoclax inhibits the apoptosis-inhibiting action of BCL-2 and proved active in treating two patients with relapsed or refractory BPDCN. A phase I clinical trial testing the safety and efficacy of the drug in BPDCN is planned but not yet in its recruiting phase.
In cases of chronic arsenic exposure, the nitric oxide levels are depleted, due to the superoxide reactions. The enzyme NO synthase (NOS) uses L-arginine to form nitric oxide, but this enzyme is inhibited by monomethylated arsenic (III) compounds.
Mapping is possible for select species only: "there are many valid examples of confined distribution patterns." For example, Clathromorphum is an arctic genus and is not mapped far south of there. However, scientists regard the overall data as insufficient due to the "difficulties of undertaking such studies."
Pedro II of Brazil died of pneumonia at the age of 66 during his exile in France in 1891. He was embalmed on 5 December, the day of his death. During the procedure, six liters (1.585 U.S. gallons) of zinc and aluminum hydrochloride were injected into his common carotid artery. Three coffins were used: an inner coffin of lead lined with white satin; a middle coffin of varnished oak; and an outer coffin of oak covered by black velvet. According to Julie Anne Taddeo, a research professor of history at the University of Maryland, lead helps keep out moisture and preserve the body for longer and prevent smells and toxins from a dead body escaping. Interred in the Royal Pantheon of the House of Braganza in Lisbon on 12 December 1891, Pedro II became a focus of pilgrimage for Brazilians visiting Portugal, with the site attracting numerous visitors. Many would visit late at night, carrying candles provided by a local guard. As they leaned over the crystal-paned inner lead coffin to view the embalmed monarch, candle wax often dripped onto the Brazilian imperial flag draped over it. In the 1910s, Brazilian educator and archivist Luís Gastão d'Escragnolle Dória traveled to Europe on a scholarship to search for historical documents related to Brazil. In a 1912 visit to the Royal Pantheon, he noted that Pedro II's body remained largely well preserved and appeared much as it had been when first placed in the coffin.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.